Type 2 diabetes in adults: management

The following documents contain the evidence that was used to develop the 2026 recommendations:

• E: Initial management
  • E1.1 Review and appendices A to C
  • E1.2 Appendix D, studies A to K
  • E1.3 Appendix D, studies L to Z
  • E2.1 Appendices E to I
  • E2.2 Appendices J and K
  • E2.3 Appendix L
  • E3
• F: Subsequent management
  • F1.1 Sections 1.1.1 to 1.1.6
  • F1.2 Sections 1.1.7 to 1.1.14
  • F2.1 Appendices A to C
  • F2.2 Appendix D1
  • F2.3 Appendix D2
  • F2.4 Appendix D3
  • F2.5 Appendix D4
  • F2.6 Appendix D5
  • F2.7 Appendix D6
  • F2.8 Appendix D7
  • F2.9 Appendix D8
  • F3
  • F4
  • F5
  • F6
  • F7
  • F8.1 (references and appendices L to Q) 
  • F8.2 (appendix R)
  • F8.3 (appendix S)
  • F9
  • F10
  • F11
  • F12
  • F13
  • F14
• Economic analyses and expert reports
  • Health inequalities report on SGLT-2 uptake 
  • Cost-effectiveness analysis of subsequent pharmacological therapy
  • Epidemiological report on SGLT-2 uptake
  • Expert testimony on transgender inclusion 
• Other supporting evidence
  • Methods
  • Committee discussion

Evidence for the 2022 recommendations can be found in the evidence review on pharmacological therapies with cardiovascular and other benefits in people with type 2 diabetes, continuous glucose monitoring in adults with type 2 diabetes and periodontal treatment to improve diabetic control in adults with type 1 or type 2 diabetes.

Evidence for the 2021 recommendations can be found in the evidence review on SGLT2 inhibitors for people with chronic kidney disease and type 2 diabetes.

In 2018 we reviewed the evidence for SGLT2 inhibitors and GLP-1 mimetics, and made no new recommendations. See the evidence review on SGLT2 inhibitors and GLP-1 mimetics for more information.

Evidence for the 2009 and 2015 recommendations can be found in the 2015 full guideline on type 2 diabetes in adults, and supporting appendices:

• 2015 full guideline on type 2 diabetes in adults
• Appendix A: Guideline Development Groups & Declarations of Interest 
• Appendix B: Scopes  
• Appendix C: Search strategies and review protocols 
• Appendix D: GRADE tables and meta-analysis result 
• Appendix E: Evidence tables
• Appendix F: Full health economics report 
• Appendix G: NICE guideline CG66 deleted text  
• Appendix H: NICE guideline CG87 deleted text  
• Appendix I: NICE guideline CG87 deleted appendix  
• Appendix J: NMA results and input data  
• Appendix K: WinBUGS code  
• Appendix L: Excluded studies  

See also the 2019 surveillance report on diabetes:

• 2019 surveillance of diabetes (NICE guidelines NG17, NG18, NG19 and NG28)
• Appendix A1: Summary of evidence from surveillance (NG17)  
• Appendix B1: Stakeholder consultation comments table (NG17)
• Appendix A2: Summary of evidence from surveillance (NG28)  
• Appendix B2: Stakeholder consultation comments table (NG28)  
• Appendix A3: Summary of evidence from surveillance (NG18)
• Appendix B3: Stakeholder consultation comments table (NG18)  
• Appendix A4: Summary of evidence from surveillance (NG19)
• Appendix B4: Stakeholder consultation comments table (NG19)